The predominant product of cyclooxygenase (COX) activity in the colon, prostaglandin (PG) E 2 promotes intestinal tumorigenesis. Expression of the PGE 2 receptor EP4 is upregulated during colorectal carcinogenesis. Therefore, we investigated the role of elevated PGE 2 -EP4 receptor signalling in the protumorigenic activity of PGE 2 by increasing EP4 receptor expression in HT-29 human colorectal cancer (CRC) cells (HT-29-EP4) by stable transfection. Elevated PGE 2 -induced EP4 receptor activity in HT-29 cells increased resistance to spontaneous apoptosis and promoted anchorage-independent growth, but had no effect on proliferation of HT-29-EP4 cells. EP4 receptor activation by PGE 2 in HT-29-EP4 cells also led to development of fluid-filled cysts, which was associated with increased tight junction protein (occludin and zonula occludens-1) expression. Overexpression of the EP4 receptor in HT-29 cells led to basal EP4 receptor signalling in the absence of exogenous PGE 2 , which was explained by autocrine activity of endogenous, COX-2-derived PGE 2 and constitutive, ligand-independent EP4 receptor activity. The predominant signalling pathway mediating antiapoptotic activity downstream of PGE 2 -EP4 receptor activation in HT-29-EP4 cells was elevation of cyclic adenosine monophosphate (cAMP) levels, which was associated with phosphorylation of cAMP-response element binding protein. EP4 receptor activation led to a small increase in phosphorylated extracellular signal-regulated kinase (ERK) 2 protein levels but inhibition of ERK phosphorylation did not abrogate the antiapoptotic activity of PGE 2 . However, PGE 2 -EP4 receptor signalling did not lead to trans-activation of the epidermal growth factor receptor in HT-29 cells. Inhibition of protumorigenic PGE 2 -EP4 receptor signalling represents a potential strategy for anti-CRC therapy that may avoid the toxicity associated with systemic COX inhibition.
The predominant product of cyclooxygenase (COX) activity in the colon, prostaglandin (PG) E 2 promotes intestinal tumorigenesis. Expression of the PGE 2 receptor EP4 is upregulated during colorectal carcinogenesis. Therefore, we investigated the role of elevated PGE 2 -EP4 receptor signalling in the protumorigenic activity of PGE 2 by increasing EP4 receptor expression in HT-29 human colorectal cancer (CRC) cells (HT-29-EP4) by stable transfection. Elevated PGE 2 -induced EP4 receptor activity in HT-29 cells increased resistance to spontaneous apoptosis and promoted anchorage-independent growth, but had no effect on proliferation of HT-29-EP4 cells. EP4 receptor activation by PGE 2 in HT-29-EP4 cells also led to development of fluid-filled cysts, which was associated with increased tight junction protein (occludin and zonula occludens-1) expression. Overexpression of the EP4 receptor in HT-29 cells led to basal EP4 receptor signalling in the absence of exogenous PGE 2 , which was explained by autocrine activity of endogenous, COX-2-derived PGE 2 and constitutive, ligand-independent EP4 receptor activity. The predominant signalling pathway mediating antiapoptotic activity downstream of PGE 2 -EP4 receptor activation in HT-29-EP4 cells was elevation of cyclic adenosine monophosphate (cAMP) levels, which was associated with phosphorylation of cAMP-response element binding protein. EP4 receptor activation led to a small increase in phosphorylated extracellular signal-regulated kinase (ERK) 2 protein levels but inhibition of ERK phosphorylation did not abrogate the antiapoptotic activity of PGE 2 . However, PGE 2 -EP4 receptor signalling did not lead to trans-activation of the epidermal growth factor receptor in HT-29 cells. Inhibition of protumorigenic PGE 2 -EP4 receptor signalling represents a potential strategy for anti-CRC therapy that may avoid the toxicity associated with systemic COX inhibition.
Introduction
Prostaglandin (PG) E 2 is the predominant eicosanoid product of the cyclooxygenase (COX)-PG synthetic pathway in the lower gastrointestinal tract (Krause and DuBois, 2001) . PGE 2 has been implicated in essential physiological processes in the colon such as electrolyte transport and motility (Krause and DuBois, 2001) . PGE 2 has also been implicated in the pathogenesis of inflammatory bowel disease, with levels of PGE 2 being increased in inflamed tissue compared with uninvolved mucosa (Krause and DuBois, 2001 ). More recently, a role for PGE 2 in intestinal tumorigenesis has been elucidated . Administration of PGE 2 to Apc Min/ þ mice (an established model of the early stages of human colorectal carcinogenesis) has been demonstrated to increase the size and multiplicity of colonic adenomas (Wang et al., 2004) . PGE 2 is believed to act in an autocrine and/or paracrine manner via a family of four cell surface or nuclear membrane G protein-coupled receptors (GPCRs) termed EP1-EP4, which are linked to distinct second messenger signalling cascades (Breyer et al., 2001) . Signalling via both EP2 and EP4 receptors is transduced predominantly by a G as protein, through which receptor activation is associated with an increase in adenylate cyclase activity and elevated intracellular adenosine-3 0 , 5 0 -cyclic monophosphate (cyclic adenosine monophosphate or cAMP) levels (Regan, 2003) . However, differences between EP2 and EP4 receptors, including ligand-induced desensitization and internalization (Desai and Ashby, 2001; Fujino et al., 2002) , coupling to an inhibitory G ai protein (Fujino and Regan, 2006) and differential signalling via protein kinase (PK) A-independent signal transduction pathways, such as that involving phosphatidylinositol 3-kinase (PI3K) and protein kinase B (PKB)/AKT (Regan, 2003) , suggest distinct roles for the two 'stimulatory' EP receptors.
The role of individual EP receptor subtypes at different stages of colorectal carcinogenesis has not been fully characterized. There is genetic and pharmacological evidence implicating a role for Ep1, Ep2 and Ep4 receptors in rodent models of intestinal adenoma and colorectal cancer (CRC) development (reviewed by Hull et al., 2004) . Increased levels of Ep1, Ep2 and Ep4 mRNAs, as well as decreased Ep3 transcript levels, are evident in mouse azoxymethane-induced CRC tissue compared with paired normal mucosa (Mutoh et al., 2002; Shoji et al., 2004) . More recently, increased levels of EP4 receptor protein have been demonstrated in malignant epithelial cells of human CRCs compared with normal colorectal mucosa (Chell et al., 2006) . Previously, investigation of EP receptor activity in CRC cells in vitro has had to rely on the use of poorly selective EP receptor agonists such as PGE 1 -alcohol and butaprost (Kiriyama et al., 1997; Ma et al., 2006) . In this way, the EP4 receptor has been implicated in the PGE 2 -mediated increase in growth, motility and invasive behaviour of human colorectal epithelial cells (Sheng et al., 2001; Chell et al., 2006) , as well as PGE 2 -mediated rescue from the antiproliferative activity of indomethacin on mouse colon 26 CRC cells (Pozzi et al., 2004) .
As EP4 receptor expression is increased during colorectal carcinogenesis, we investigated the role of PGE 2 -EP4 receptor signalling cells during colorectal carcinogenesis using a model of EP4 receptor overexpression in HT-29 human CRC cells. Herein, we implicate PGE 2 signalling, via elevated EP4 receptor levels, in the protumorigenic progression of intestinal epithelial cells.
Results

EP4
receptor mRNA levels, measured by quantitative, real-time polymerase chain reaction (PCR), were increased significantly in human CRC tissue compared with paired normal colorectal mucosa (mean 65% increase (95% confidence interval 29-195%), n ¼ 5; P ¼ 0. 02, one-sample t-test). These data were consistent with the findings from an immunohistochemical study of EP4 receptor protein in human CRCs (Chell et al., 2006) and, together with this previous report, provided the rationale for development of a cellular model of increased EP4 receptor expression in human CRCs.
In order to localize cellular EP4 receptor protein accurately, we tagged the human (h) EP4 receptor with a V5 epitope by subcloning hEP4 receptor cDNA into the pTracer vector. Initial experiments testing the function of the hEP4-V5 receptor construct were performed by transient transfection of COS-7 monkey kidney cells and 293T human embryonic kidney cells. Figure 1a demonstrates that hEP4-V5 receptor protein was detectable in total protein lysates of COS-7 and 293T cells transiently transfected with pTracer-hEP4, but not mock transfected cells or COS-7 cells that expressed native, untagged hEP4 receptor from the transfected pCEP4-EP4 vector. Transfection with a pTracer vector expressing LacZ-V5 acted as a positive control (Figure 1a ). Both cell types expressed a hEP4-V5 receptor species of approximately 52 kDa but differed in the expression of a larger molecular weight form of EP4 (Figure 1a) . The larger form of the EP4 receptor was not detected following lysis of pTracer-hEP4-transfected COS-7 cells in the absence of detergent, but was still present in a pTracer-hEP4-transfected 293T-cell lysate produced in a similar manner (data not shown), suggesting that, in COS-7 cells, this species represents a membrane-bound form of the receptor that requires detergent-solubilization for detection by Western blotting. Immunofluorescence on hEP4-V5 receptor-transfected COS-7 cells in the presence of solvent carrier alone demonstrated prominent hEP4-V5 immunoreactivity at the cell membrane (Figure 1b) . However, upon stimulation with 1 mM PGE 2 for 60 min, membranous hEP4-V5 receptor immunoreactivity became almost exclusively cytoplasmic ( Figure 1b) . As expected, PGE 2 signalling via the V5-tagged hEP4 receptor in 293T cells, in the presence of the phosphodiesterase IV inhibitor rolipram, was associated with a greater than 10-fold increase in intracellular cAMP levels ( Figure 1c ). The PGE 2 -induced rise in cAMP levels mediated by the hEP4-V5 receptor was of similar magnitude to that seen in cells transfected with native EP4 (pCEP4-hEP4; Figure 1c ). Transfection of 293T cells with pTracer-hEP4 was also associated with a PGE 2 -mediated increase in b-catenin/ T-cell factor (TCF)-mediated transcription (Figure 1d ), consistent with previously published data (Fujino et al., 2002) . Taken together, these data confirm intact EP4 receptor trafficking and downstream signalling following transfection with pTracer-hEP4.
Having confirmed the functionality of the hEP4-V5 receptor, we chose HT-29 human CRC cells to produce EP4 receptor overexpressing colorectal epithelial cells, thereby mirroring the increase in epithelial cell EP4 protein levels that occurs in human CRCs (Chell et al., 2006) . The HT-29 cell line was particularly suitable for experiments testing PGE 2 -EP4 receptor signalling and function as HT-29 cells do not produce detectable endogenous PGE 2 (Hsi et al., 2000; Shao et al., 2000) , do not demonstrate an elevation in intracellular cAMP levels upon addition of exogenous PGE 2 (Cassano et al., 2000) and contain EP4 receptor mRNA, but not transcripts for the other EP receptor subtypes coupled to cAMP signalling (Cahlin et al., 2005; Colucci et al., 2005) . HT-29 cells were transfected with the pTracerhEP4 vector in the presence of the selection agent blasticidin. Stably transfected EP4 receptor overexpressing (HT-29-EP4) and empty vector-transfected (HT-29-con) single-cell clones were then obtained by limited dilution cloning and culture in the continued presence of blasticidin.
Untreated EP4 receptor-overexpressing HT-29-EP4 cells exhibited the same membranous distribution of V5-tagged EP4 receptor as transiently transfected COS-7 cells (Figure 2a and b) . HT-29-EP4 cells also underwent ligand (PGE 2 )-induced EP4 receptor internalization (Figure 2c ). By contrast, there was no specific V5 immunofluorescence detected in HT-29-con cells (Figure 2d ), thus confirming the specificity of the V5 immunoreactivity in HT-29-EP4 cells.
In keeping with data from Cassano et al. (2000) , cAMP was not detected in HT-29-con cells even after exposure to 1 mM PGE 2 for 5 min (data not shown). However, HT-29-EP4 cells exhibited a marked elevation of intracellular cAMP levels upon stimulation with PGE 2 , at concentrations as low as 50 nM, for 5 min (Figure 2e ). Exposure of HT-29-EP4 cells to 1 mM PGE 2 , a concentration at which PGE 2 has been used widely in previous in vitro studies, was not associated with a further stepwise increase in the cAMP response of HT-29-EP4 cells above that seen with 50 nM PGE 2 (Figure 2e ). Further evidence implicating the EP4 receptor in the differential cAMP response of stably transfected HT-29-EP4 cells was obtained by demonstrating that the EP2 receptor-selective agonist butaprost did not induce an increase in cAMP levels in HT-29-EP4 cells, unlike PGE 1 -alcohol (PGE 1 -OH), which at low concentrations (10 nM), is a relatively specific agonist for the EP4 receptor (Kiriyama et al., 1997 Figure 2e ). We also tested the EP4 receptor antagonist ONO-AE3-208 in this assay system and determined that approximately 90% inhibition of the cAMP response of HT-29-EP4 cells to 1 mM PGE 2 occurred with 10 mM ONO-AE3-208 (Figure 2f ), a concentration consistent with that used in a previous in vitro study using mouse macrophages (Pavlovic et al., 2006) . There was a small elevation in cAMP levels observed in basal (non-PGE 2 -treated), rolipram-treated HT-29-EP4 cells compared with HT-29-con cells ( Figure 2e ) and ONO-AE3-208 also decreased intracellular cAMP levels in HT-29-EP4 Protumorigenic activity of PGE 2 -EP4 receptor signalling G Hawcroft et al cells in the absence of exogenous PGE 2 ( Figure 2f ). One possible explanation is that HT-29-EP4 cells produce PGE 2 , which could drive EP4 receptor activity in the absence of exogenously added PGE 2 . However, PGE 2 was not detectable by conventional immunoassay of medium conditioned by HT-29-EP4 (or HT-29-con) cells, even after treatment with the EP4 receptor agonist PGE 1 -OH (10 nM or 1 mM). Alternatively, we used the non-selective COX inhibitor indomethacin and the selective COX-2 inhibitor SC236, at non-toxic concentrations (Smith et al., 2000; Ko et al., 2002) , in order to determine whether low level COX-dependent PGE 2 synthesis, below the detection limit of the immunoassay, accounted for basal EP4 receptor activity in HT-29-EP4 cells. Incubation with indomethacin and SC236 (both 1 mM) for 30 min was associated with a 54.5712.7 (standard error of the mean (s.e.m.)) % and 60.0710.0% decrease in intracellular cAMP levels, respectively, in HT-29-EP4 cells (n ¼ 3 in two independent experiments). Importantly, prior incubation with a 10-fold higher concentration of indomethacin did not produce any further inhibition of cAMP production in HT-29-EP4 cells (47.877.7%) suggesting that the response to 1 mM concentrations of the COX inhibitors was maximal. These data suggest that ligand-dependent EP4 receptor activation by low levels of PGE 2 (below the detection level of a high-sensitivity immunoassay) is responsible for a proportion (approximately 60%) of basal EP4 receptor activity in HT-29-EP4 cells and that COX-2 is the predominant COX isoform responsible for trace PGE 2 synthesis in HT-29-EP4 cells. Overall, the immunolocalization and cAMP data confirmed that the transfected hEP4 receptor was also functional in HT-29 cells and provided the impetus to study further the phenotype of HT-29-EP4 cells.
The most obvious phenotypic change in untreated HT-29-EP4 cells was the presence of cysts in the HT-29 multi-cell layer (Figure 3a ), which were not evident in untreated HT-29-con (Figure 3b ) or parental HT-29 cell cultures (data not shown). Formation of cysts was a dynamic process with the expansion and disappearance of individual cysts over time demonstrated by time-lapse photomicroscopy (see Supplementary video file Figure  S1 ). Mucin histochemistry revealed that the cysts were Alcian Blue (pH 2.5)-negative and Periodic Acid-Schiffnegative (data not shown).
We hypothesized that the cysts represented accumulation of fluid within the cell multilayer due to increased electrolyte transport and/or decreased paracellular permeability of HT-29-EP4 cell cultures. Confocal immunofluorescence for tight junction (TJ) proteins zonula occludens (ZO)-1 and occludin demonstrated coordinated upregulation of both TJ proteins in cells surrounding the cyst spaces (Figure 3c ). Expression of ZO-1 and occludin was largely restricted to cells surrounding the cysts with only small areas of discontinuous ZO-1 and occludin immunoreactivity being apparent in non-cystic areas of HT-29-EP4 and HT-29-con cell layers (see Supplementary Figure S2 ). Electron microscopy demonstrated that TJs and desmosomes were prominent in HT-29-EP4 cells (Figure 3d ). In order to determine further the mechanistic basis of cyst formation we developed a quantitative, photomicroscopic assay of the cyst cross-sectional area measured at any given time. As described previously (Ophir et al., 1995) , the adenylate cyclase activator forskolin induced cyst formation in HT-29-con cells ( Figure 3e ) implying a role for cAMP signalling. However, PGE 2 did not promote visible cyst formation in HT-29-con cells (data not shown). By contrast, PGE 2 increased cyst formation in HT-29-EP4 cells (to a similar degree to forskolin), which was inhibited by ONO-AE3-208, thereby implicating PGE 2 -EP4 receptor-cAMP signalling in cyst formation in HT-29 cell cultures in vitro. Importantly, the Na þ /K þ -ATPase inhibitor ouabain inhibited basal and PGE 2 -induced cyst formation almost completely in HT-29-EP4 cells (Figure 3e ) implying that active electrolyte transport is necessary for EP4 receptordependent cyst formation in HT-29-EP4 cells, in combination with increased TJ protein expression.
As reduced apoptosis is a hallmark of carcinogenesis (Wright and Duckett, 2005) and cAMP signalling is recognized to promote resistance to apoptosis in vitro (Hoshino et al., 2003; Nishihara et al., 2004) , we next investigated the role of PGE 2 -EP4 receptor signalling in the apoptotic potential of HT-29 cells. Adherent human CRC cells, including HT-29 cells, become detached during apoptosis (Elder et al., 1997; Gardner et al., 2004) . Therefore, we used the established technique of non-adherent cell counting in order to quantitate the degree of apoptosis (Elder et al., 1997; Gardner et al., 2004) . Preliminary experiments confirmed that the nonadherent cell count accurately reflected the degree of apoptosis in stably transfected HT-29 cell cultures (mean (s.e.m.) 98.4 (0.4) % non-adherent HT-29-con cells and 98.8 (0.7) % non-adherent HT-29-EP4 cells (both n ¼ 6) had apoptotic morphology by fluorescence microscopy). Exogenous PGE 2 (1 mM) had no effect on In HT-29-EP4 cells, the antiapoptotic effect of PGE 2 was antagonized by ONO-AE3-208 (Figure 4a ). In keeping with data from the cAMP assay, inhibition of the antiapoptotic effects of PGE 2 on HT-29-EP4 cells by ONO-AE3-208 only occurred at a concentration of 10 mM, unlike lower concentrations (10 nm-1 mM), which did not reverse PGE 2 activity in our non-adherent cell counting assay (data not shown). Taken together, these data implicate elevated EP4 receptor levels in PGE 2 -mediated protection of HT-29 cells from apoptosis. Protumorigenic activity of PGE 2 -EP4 receptor signalling G Hawcroft et al By contrast, exogenous PGE 2 (1 mM) did not increase the proliferation rate of either HT-29-con or HT-29-EP4 cells over a period of 72 h as measured by adherent cell counting (Figure 4b ) or a DNA synthesis assay (Figure 4c ). The number of adherent, viable, untreated HT-29-EP4 cells increased more quickly over time than PGE 2 -untreated HT-29-con cells (Figure 4b) . However, proliferation, as measured by 5-bromo-2 0 -deoxyuridine (BrdU) incorporation, did not differ between PGE 2 -untreated HT-29-EP4 cells and HT-29-con cells (Figure 4c ). Overall, in this human CRC model, it can be concluded that increased PGE 2 -EP4 receptor activity does not stimulate a significant proliferative response in HT-29 cells.
Another cardinal feature of tumorigenic behaviour of transformed cells is the ability to grow in an anchorageindependent manner. Control-transfected HT-29 cells exhibited low efficiency anchorage-independent growth in soft agar (Figure 5 ), which was not affected by treatment with PGE 2 (Figure 5 ). However, untreated HT-29-EP4 cells demonstrated a greater than fourfold increase in cell colony formation, which was increased further in the presence of exogenous PGE 2 ( Figure 5 ). Importantly, ONO-AE3-208 reduced the colony-forming efficiency and colony size of untreated and PGE 2 -treated HT-29-EP4 cells ( Figure 5 ). These data suggest a role for increased EP4 receptor signalling in promotion of anchorage-independent growth of HT-29 cells.
Several signalling pathways have been described downstream of EP4 receptor activation, including protein kinase A (PKA) activation, PI3K signalling and extracellular signal-regulated kinase (ERK) activation, in transfected EP4 receptor-expressing 293T HEK cells (Fujino et al., 2002 (Fujino et al., , 2003 (Fujino et al., , 2005 . However, the relevance of these findings to malignant human colorectal epithelial cells with increased EP4 receptor expression is unclear. Therefore, we studied signalling downstream of EP4 receptor activation in HT-29 human CRC cells.
As elevation of cAMP levels was a prominent feature of PGE 2 -induced activation of the EP4 receptor in HT-29-EP4 cells, we firstly examined activation of the transcription factor cAMP-response element binding protein (CREB) in response to EP4 receptor activation by PGE 2 . HT-29-con cells contained only low levels of phosphorylated (p)CREB protein and the phosphorylated form of the related CREB family member activating transcription factor 1 (ATF1) relative to the total intracellular CREB level (Figure 6a) . In a pattern consistent with the cAMP response to PGE 2 treatment of HT-29-con and HT-29-EP4 cells (Figure 2e ), PGE 2 did not induce phosphorylation of CREB/ATF1 in HT-29-con cells but increased pCREB/pATF1 levels in HT-29-EP4 cells in an EP4 receptor-dependent manner (Figure 6a ). Phosphorylation of CREB following EP4 receptor activation by PGE 2 implicates PKA signalling downstream of the EP4 receptor (Mayr and Montminy, 2001 ). However, the PKA inhibitor H89 only partially reversed (by approximately 50%) PGE 2 -induced resistance to apoptosis of HT-29-EP4 cells, suggesting a Protumorigenic activity of PGE 2 -EP4 receptor signalling G Hawcroft et al contribution from a PKA-independent signalling pathway towards EP4 receptor-mediated antiapoptotic activity in HT-29 cells (Figure 6b ). One candidate PKA-independent pathway is ERK activation, as previous studies have described EP4 receptor-dependent ERK signalling in mouse colon 26 CRC cells (Pozzi et al., 2004) and PGE 2 -induced ERK signalling in HCA-7 human CRC cells (Wang et al., 2005) . Treatment with PGE 2 did not alter the cellular levels of phosphorylated or total ERK1 and ERK2 in HT-29-con cells (data not shown). However, treatment with 1 mM PGE 2 increased pERK2 levels, relative to the total ERK1/2 content, in HT-29-EP4 cells at 60 min (Figure 6c ). This effect was abrogated in the presence of ONO-AE3-208 (Figure 6c ). EP4 receptor-mediated induction of pERK2 was also inhibited by 10 mM H89 (Figure 6c ), implying that ERK activation is, in fact, linked to PKA activation in HT-29 cells. By contrast, incubation with 100 ng/ml rhEGF for 5 min was associated with a far greater induction of pERK in HT-29 cells (Figure 6c ). In keeping with relatively minor pERK induction downstream of EP4 receptor activation in HT-29 cells overexpressing the EP4 receptor, preincubation with either of two MAP kinase (MEK) inhibitors PD98059 and U0126 did not abrogate the antiapoptotic activity of PGE 2 -EP4 receptor signalling in HT-29-EP4 cells (Figure 6d) . PGE 2 has been implicated in trans-activation of the epidermal growth factor receptor (EGFR) in several cell types in vitro, including human CRC cells (Pai et al., 2002; Buchanan et al., 2003 Buchanan et al., , 2006 . Therefore, we used our HT-29 human CRC model in order to investigate the involvement of the EP4 receptor in PGE 2 -mediated EGFR trans-activation. Contrary to a previous report (Pai et al., 2002) , we did not observe trans-activation of EGFR by PGE 2 incubated for varying times (5-60 min) with HT-29-con cells (Figure 7a and b) using two independent techniques (phospho-tyrosine (PY) detection in immunoprecipitated EGFR and cell-based immunoassay of pEGFR), although this cell line does express functional EGFR, as its direct ligand EGF induced receptor phosphorylation in both assays ( Figure  7a and b) . Furthermore, in order to confirm that the lack of PGE 2 -mediated EGFR trans-activation was not due to selection of an EGFR-null cell clone, we demonstrated that PGE 2 did not induce EGFR phosphorylation in non-transfected parental HT-29 cells (data not shown). Similarly, treatment with 1 mM PGE 2 for 15 min, or a 10-fold higher concentration of PGE 2 for 60 min, did not increase EGFR phosphorylation in HT-29-EP4 cells (Figure 7a and b) . Therefore, we have found no evidence that the EP4 receptor mediates PGE 2 -mediated EGFR trans-activation in HT-29 cells. Consistent with the absence of PGE 2 -induced EGFR activation, we did not observe an increase in pPKB/ AKT levels in HT-29-EP4 cells treated with PGE 2 (data not shown). This suggests that this important cell survival signalling pathway does not mediate the protumorigenic activity of the EP4 receptor in HT-29 cells.
Discussion
Recent clinical data suggest that long-term selective COX-2 inhibition is associated with an increased risk of myocardial infarction and stroke (Grosser et al., 2006) . However, COX-2 inhibition has potent antineoplastic activity (Hull, 2005) . Therefore, it is important to develop strategies that harness the beneficial anticancer effects of COX inhibition, while avoiding the vascular toxicity associated with systemic COX-2 inhibition. Our findings suggest that inhibition of PGE 2 -EP4 receptor signalling may be a valid anti-CRC strategy, particularly as preclinical studies have suggested that EP4 receptor antagonism may have a favourable side effect profile (Kato et al., 2005; Pavlovic et al., 2006) . Some phenotypic changes, including cyst formation, increased anchorage-independent growth and elevated intracellular cAMP levels, were evident in HT-29-EP4 cells in the absence of exogenously added PGE 2 . Experiments with COX inhibitors demonstrated that approximately 60% of the basal EP4 receptor activity in PGE 2 -untreated HT-29-EP4 cells, as measured by the cAMP response, was explained by autocrine effects of COX-2-derived PGE 2 . One explanation for the increased cAMP signalling in HT-29-EP4 cells, which was not abrogated by COX-2 inhibition, is that increased expression of the EP4 receptor in HT-29-EP4 cells may have uncovered a degree of constitutive, ligand-independent EP4 receptor activity, similar to that described for many other GPCRs (Seifert and WenzelSeifert, 2002) . Potential PGE 2 -independent EP4 receptor activity occurring in colorectal tumours exhibiting elevated levels of the EP4 receptor has important implications for the efficacy of anticancer therapies targeting PGE 2 synthesis, for example, COX inhibitors.
In our model of EP4 receptor overexpression in HT-29 cells, PGE 2 -EP4 receptor signalling was linked predominantly to cAMP signalling and low level ERK activation, but not PKB/AKT signalling, in contrast to findings from a model of EP4 receptor expression in 293T cells, in which cAMP signalling appears to play a relatively minor role in signal transduction (Fujino al., 2002, 2003, 2005) . Therefore, this study highlights the importance of investigating EP receptor signalling in a relevant cellular context. EP4 receptor-dependent antiapoptotic activity of PGE 2 in HT-29 cells occurred via a mechanism involving cAMP-PKA signalling but not ERK activation or PI3K-PKB/AKT signalling. By contrast, cAMP-dependent suppression of apoptosis by PGE 2 in T84 human CRC cells seems to occur via mechanisms dependent on ERK and p38 mitogenactivated (MA) PK signalling, but not PKA (Nishihara et al., 2004) . There is clearly significant heterogeneity in signalling pathways mediating the antiapoptotic and proproliferative activities of PGE 2 between different CRC cells in vitro (Sheng et al., 2001; Nishihara et al., 2004; Pozzi et al., 2004; Holla et al., 2005) . This may be due to interplay between the EP receptor subtypes that are variably present on different CRC cell lines. For example, HT-29 and T84 human CRC cell lines both express EP4 receptor transcripts (Colucci et al., 2005; Cahlin et al., 2005 , Nishihara et al., 2003 , but T84 cells also contain EP2 receptor mRNA, unlike HT-29 cells (Nishihara et al., 2003) . PKA activation only accounted for approximately 50% of the antiapoptotic activity related to PGE 2 -EP4 receptor signalling in HT-29 cells. It is increasingly recognized that cAMP can also signal in a PKAindependent manner via the cAMP-dependent guanine nucleotide exchange factor Epac1, which, in turn activates the Ras-GTPase Rap1 (Misra and Pizzo, 2005) . It will be important to define the role of Epac1-Rap1 signalling downstream of EP4 receptor activation in human CRC cells.
PGE 2 -dependent EGFR activation in human CRC cells also appears to be variable, with responsive (LS-174) and unresponsive (DLD-1) cell lines described (Buchanan et al., 2003 (Buchanan et al., , 2006 Castellone et al., 2005) . In our study, we found no evidence of PGE 2 -induced transactivation of the EGFR in HT-29 cells, which others have noted express constitutively active EGFR (Keese et al., 2005) . PGE 2 -mediated EGFR trans-activation in other human cancer cell lines involves other EP receptor subtypes. For example, the EP1 receptor has been linked to EGFR phosphorylation in CCLP1 human cholangiocarcinoma cells (Han and Wu, 2005) and Hep3B human hepatocellular carcinoma cells (Han et al., 2006) . Moreover, PGE 2 has been demonstrated to transactivate the EGFR via the EP2 receptor in Ishikawa human endometrial cancer cells (Sales et al., 2004) . However, the EP4 receptor may play a role in EGFR trans-activation in some cell types as the EP4 receptor antagonist L161982 abrogated PGE 2 -induced EGFR phosphorylation in rat cardiac myocytes (Mendez and LaPointe, 2005) .
Overexpression of the EP4 receptor in HT-29 cells has also provided novel insights into the relationship between PGE 2 signalling and paracellular permeability and the ion transport properties of intestinal epithelial cell cultures. Our data implicate EP4 receptor activation in TJ assembly in HT-29 cells that normally do not exhibit TJs (Ophir et al., 1995) . Interestingly, cAMP has been demonstrated to increase ZO-1 and occludin protein levels in human microvascular endothelial cells (Dye et al., 2001) and TJ multiplicity in intact mesenteric blood vessels in frogs (Adamson et al., 1998) , although there has been no previous study linking cAMP signalling and TJ formation in epithelial cells. In summary, we have demonstrated that increased PGE 2 -EP4 receptor signalling that occurs in CRCs drives protumorigenic behaviour of HT-29 cells, via a mechanism that involves cAMP-PKA signalling, but not ERK activation or AKT phosphorylation downstream of EGFR activation. By comparison with disparate sources of data from studies using other cell lines (Sheng et al., 2001; Buchanan et al., 2003; Hoshino et al., 2003; Nishihara et al., 2004) , it is clear that similar phenotypic responses to exogenous PGE 2 can be subserved by different signalling pathways acting in a cell-specific manner. In future, it will be important to determine the complete EP receptor profile, the PGE 2 content and the degree of ligand-independent EP receptor activity of colorectal tumours at different stages of carcinogenesis in order to accurately target PGE 2 -EP receptor signalling as a therapeutic anti-CRC strategy.
Materials and methods
Reagents and antibodies PGE 2 , PGE 1 -OH and butaprost were obtained from Cayman Chemical Co. (Ann Arbor, MI, USA) and dissolved in either DMSO or ethanol (minimum 1 mM). The EP4 receptor antagonist ONO-AE3-208 (10 mM in DMSO) was a gift from ONO Pharmaceutical Co., Osaka, Japan. SC236 (20 mM in DMSO) was a gift from Pfizer Inc., New York, NY, USA. Indomethacin (100 mM in DMSO) was purchased from Sigma Chemical Co., Poole, UK. Rolipram (50 mM in DMSO), H89, PD98059, U0126 (all 10 mM in DMSO), forskolin (20 mM in DMSO) and ouabain (10 mM in methanol) were purchased from Calbiochem (Nottingham, UK). Blasticidin (5 mg/ml in distilled water) was from Invitrogen, Paisley, UK. Recombinant human epidermal growth factor (EGF) was obtained from R&D Systems Ltd, Abingdon, UK.
Antibodies to pERK1 and 2 (Thr202/Tyr204), total ERK1/2, pCREB (Ser133) and total CREB, pPKB/AKT (Ser473) and total PKB/AKT, and PY were obtained from Cell Signalling Technology Inc. (Beverly, MA, USA). Anti-EGFR antibody (clone 1005) was obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Antibodies to ZO-1 and occludin were obtained from Zymed (San Francisco, CA, USA). Antibody to human b-actin was obtained from Sigma Chemical Co. Antibody to the V5 epitope was purchased from Invitrogen. Horseradish peroxidase-conjugated secondary antibodies were obtained from DAKOcytomation Ltd (Ely, UK). Alexa Fluor 488-and 594-conjugated secondary antibodies were obtained from Molecular Probes, Paisley, UK (Invitrogen).
Cell culture COS-7 cells (a gift from Dr Helen Ardley, University of Leeds) and 293T cells (a gift from Dr Gina Scott, University of Leeds) were cultured in Dulbecco's modified Eagle medium (Invitrogen) with 10% (v/v) foetal bovine serum (FBS). HT-29 cells (ECACC, Porton Down, UK) were cultured in Rosewell's Park Memorial Institute 1640 medium containing Glutamax supplemented with 10% (v/v) FBS, 1000 U/ml penicillin and 500 U/ml streptomycin (all Invitrogen). Viable cell counts were obtained using a haemocytometer and exclusion of 0.04% (v/v) Trypan blue (Sigma).
Overexpression of the human EP4 receptor
Human (h) EP4 receptor cDNA (Accession number L28175, nucleotides 370-1877) was obtained from pCEP-EP4 (a gift from J Regan, Tucson, AZ, USA Fujino et al., 2002) by PCR using PfuTurbo DNA polymerase (Stratagene, La Jolla, CA, USA) (951C for 5 min, 951C for 45 s, 551C for 45 s, 721C for 2 min for 35 cycles, then 721C for 10 min, with forward, 5 0 -CAGTGTGCTGGAATTCTGC-3 0 and reverse, 5 0 -TATA CATTTTTCTGATAAGTTCAGT-3 0 primers) and then inserted (nucleotides 370-1851) into the pTracer-EF/Bsd vector (Invitrogen) in-frame with a C-terminal V5 epitope-polyhistidine tag using EcoRI and EcoRV. DNA sequencing confirmed high fidelity PCR cloning and correct gene orientation.
Transient transfection of COS-7 and 293T cells was achieved using 1 mg pTracer-EP4 and Genejuice (Novagen, Madison, WI, USA) in the presence of 2.5% (v/v) FBS overnight at 371C. Transfection efficiency was monitored by fluorescence microscopy for cycle 3-green fluorescent protein. The same protocol was used for production of stable HT-29 cell clones, followed by dilution cloning in selection medium containing 10 mg/ml blasticidin. Dual-luciferase assay of the b-catenin/ TCF reporter pTOPflash was performed as described (Gardner et al., 2004) .
Electron microscopy HT-29 cells on glass coverslips were fixed in 3% (w/v) glutaldehyde in 0.1 M phosphate buffer overnight at 41C. Following a wash with phosphate buffer for 10 min, coverslips were treated with 2% (w/v) osmium tetroxide in phosphate buffer for 1 h with mixing. After passing through a graded alcohol series, coverslips were embedded in resin (Agar Scientific Ltd, Stansted, UK) and incubated overnight at 701C. Embedded cells were removed from the coverslip with a razor blade and re-embedded perpendicularly in fresh resin as above. Transmission electron microscopy on ultrathin sections was performed with a Jeol 100-S electron microscope.
Quantification of the cyst area of HT-29 cells
Phase-contrast photomicrographs of HT-29 cells in 35 mm wells were obtained using an Olympus CKX41 microscope. The total cyst area in four quadrant images from each well was calculated using Lucia G software (Nikon UK Ltd, Kingston-upon-Thames, UK).
Immunoblot analysis and immunoprecipitation
Cells were lysed in ice-cold 50 mM Tris-HCl (pH 7.2). containing 0.137 M sodium chloride, 1% (v/v) Brij 96, 1 mM ethylenediaminetetra-acetic acid, 200 mM 4-(2-aminoethyl)-benzenesulphonyl fluoride, 20 mM leupeptin and 1 mM pepstatin (all Sigma) and then passed through a QIAshredder homogenizer (QIAGEN Ltd, Crawley, UK). For phosphoprotein analysis, cells were cultured in serum-free medium for 24 h and lysed in PhosphoSafet extraction buffer (Novagen). Immunoblot analysis was performed as described (Gardner et al., 2004) , except that membranes were blocked with 5% (w/v) dried skimmed milk in phosphate-buffered saline (PBS) for 1 h at 201C. Membranes were probed with primary antibodies (1:1000 dilution except b-actin (1/5000)) in PBS containing 3% (w/v) dried skimmed milk for 1 h at 201C or in PBS in the presence of 5% (w/v) bovine serum albumin and 0.1% (v/v) Tween-20 (both Sigma) for 16 h at 41C. Horseradish peroxidase-conjugated secondary antibodies were diluted 1/ 2000 in PBS plus 5% (w/v) dried skimmed milk powder and incubated with blots for 1 h at 201C. Immunoreactivity was visualized using ECL chemiluminescence (Pierce, Chester, UK).
For immunoprecipitation, cells were lysed in radioimmunoprecipitation assay buffer (Cell Signalling) containing phosphatase inhibitor cocktail 2 (Sigma) and 1 mM sodium orthovanadate, at 41C. EGF receptor was pulled down using 4 mg/ml anti-EGFR antibody for 24 h at 41C and then protein G-sepharose (Amersham Pharmacia, Little Chalfont, UK) for 18 h at 41C. Immunodetection of PY and EGFR was performed as above.
pEGFR (Tyr1173) and total EGFR expression was measured by a cell-based immunoassay (FACE; Active Motif, Carlsbad, CA, USA). All EGFR experiments were performed on cells that had undergone serum starvation for 24 h beforehand.
Indirect immunofluorescence
Cells on glass coverslips were fixed in 100% methanol at À201C for 10 min and washed twice with PBS before incubation with primary antibody (V5, 1/200; ZO-1, 1/50; occludin, 1/25) in PBS containing 1% (w/v) dried skimmed milk, 0.1%. (v/v) Tween-20 for 2 h at 201C. Secondary antibodies (1/400 dilution) were incubated with coverslips in 1% (w/v) dried skimmed milk powder in PBS for 1 h at 201C. Cells were then treated with 0.2 mg/ml 4 0 , 6 diamidino-2-phenylindole (DAPI) in PBS for 10 min followed by PBS washes (3 Â 5 min). Coverslips were mounted in MOWIOL (Calbiochem).
Assay of intracellular cAMP content
HT-29 cells (1 Â 10 6 ) were incubated overnight in triplicate 35 mm wells. Cells were pretreated with 50 mM rolipram for 10 min before addition of 10 mM ONO-AE3-208, followed 45 min later by EP receptor agonists. COX inhibitors were added 30 min before cAMP assay. Intracellular cAMP content was assayed using a Biotrak cAMP immunoassay (Amersham Pharmacia; non-acetylation protocol).
Immunoassay of PGE 2 levels in cell-conditioned medium HT-29-con and HT-29-EP4 cells (2.5 Â 10 5 ). were seeded in triplicate in 24-well plates. At 24 h, fresh medium (0.5 ml) was replaced with or without PGE 1 -OH (10 nM or 1 mM) for 4 h before further replacement by fresh medium. Cell-free conditioned medium was collected after 24 h and adherent, viable cells were counted. PGE 2 levels were measured by a highsensitivity immunoassay (R&D Systems Ltd). Based on the minimum detectable dose of PGE 2 (10.1 pg/ml), the assay could detect PGE 2 in cell-conditioned medium above a level of 2 pg/ml/10 5 cells.
Measurement of cell proliferation and apoptosis
HT-29-con and HT-29-EP4 cells (2 Â 10 6 ) were seeded in triplicate 35 mm wells and incubated overnight. Medium containing ONO-AE3-208 or carrier alone was replaced 60 min before addition of PGE 2 or carrier alone to the cultures. At 24 h, non-adherent cells were harvested by centrifugation at 800 g for 5 min and cells resuspended in 4% (w/v) paraformaldehyde in PBS and stored at 41C. Fluorescence microscopy of a minimum 100 DAPI-stained nonadherent cells was performed as described (Ko et al., 2002) . Apoptosis was also measured in combined non-adherent and adherent cells (detached with Accutase (Sigma)) using an Annexin V:FITC Apoptosis Detection Kit (BD Pharmingen, San Diego, CA, USA). For these experiments, 5 Â 10 5 cells were seeded into 35 mm wells and analysed at 24 h using a BD LSR II Flow Cytometer (BD Biosciences, San Jose, CA, USA). Adherent cell counting experiments were performed by plating 5 Â 10 4 cells in triplicate 35 mm wells and counting trypsinized, Trypan blue-negative cells at 24, 48 and 72 h. BrdU incorporation assays (Roche Diagnostics Ltd, Lewes, UK) were performed on 1 Â 10 3 cells per well in 96-well plates between 24 and 72 h. In both assays, fresh medium containing PGE 2 and/or ONO-AE3-208 was replaced at 48 h.
Assay of anchorage-independent growth capability HT-29-con or HT-29-EP4 cells (5 Â 10 4 ) were cultured in 0.4%. (w/v) agar as described (Ko et al., 2002) . Fresh medium containing working concentrations of PGE 2 and/or ONO-AE3-208 was added every 48 h. On day 14, colonies greater than 200 mm in diameter were counted. The % colony formation efficiency was calculated as the (number of colonies/5 Â 10 4 ) Â 100.
Real-time PCR of EP4 receptor mRNA levels in human colorectal tissue One microlitre of each cDNA from the human colon matched cDNA pair panel (Clontech, Mountain View, CA, USA) was amplified by SYBR Green real-time PCR using an ABI Prism 7700 Sequence Detection System (Applied Biosystems, Warrington, UK). Primers (0.3 pmol each) for human EP4 receptor cDNA were; forward dTCTTACTCATTGCCACCTCCCT and reverse dCTTGGCTGATATAACTGGTTGACG. Reactions were incubated at 501C for 2 min and then 951C for 10 min, followed by 50 cycles consisting of 951C for 15 s and 601C for 1 min. Differences in transcript levels between paired tumour/normal samples were determined by the comparative 2 ÀDCt method.
